Spectrum of amyloglucosidase mutations in Asian Indian patients with Glycogen storage disease type III

• Published in: American journal of medical genetics. Part A Vol. 182; no. 5; pp. 1190 - 1200
• Main Authors: Perveen, Shama, Gupta, Neerja, Kumar, Manoj, Kaur, Punit, Chowdhury, Madhumita R., Kabra, Madhulika
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.05.2020; Wiley Subscription Services, Inc
• Subjects: AGL gene; Alleles; Asian Continental Ancestry Group - genetics; Cardiac muscle; Cardiomyopathy; Child; Child, Preschool; Diagnosis; Exons; Exons - genetics; Female; Gene frequency; Gene Frequency - genetics; Genetic Predisposition to Disease; Glucan 1,4-alpha-Glucosidase - genetics; Glucan 1,4-alpha-Glucosidase - metabolism; Glycogen; glycogen debranching enzyme; Glycogen storage disease type III; Glycogen Storage Disease Type III - epidemiology; Glycogen Storage Disease Type III - genetics; Glycogen Storage Disease Type III - pathology; Growth rate; Humans; Hypoglycemia; India; Liver - enzymology; Liver - metabolism; Liver - pathology; Male; molecular modeling; Molecular modelling; Mutation; Mutation - genetics; mutation spectrum; Myopathy; Seizures; Storage diseases; Structure-function relationships; glycogen debranching enzyme; mutation spectrum; AGL gene; Glycogen storage disease type III; molecular modeling; India
• ISSN: 1552-4825; 1552-4833
• DOI: 10.1002/ajmg.a.61547

Glycogen storage disease type III (GSD III) is a rare autosomal recessive inborn error of glycogen degradation pathway due to deficiency or reduced activity of glycogen debranching enzyme (GDE) that results in accumulation of abnormal glycogen in the liver, muscle, and heart. The cardinal hallmarks are hepatomegaly, fasting hypoglycemia, seizures, growth retardation, progressive skeletal myopathy, and cardiomyopathy in few. To date, 258 mutations in amyloglucosidase (AGL) gene have been identified worldwide. However, the mutation spectrum in the Asian Indian region is yet to be well characterized. We investigated 24 patients of Asian origin from 21 unrelated families with a provisional diagnosis of GSD III based on clinical and biochemical criteria. Molecular diagnosis was assessed by bidirectional sequencing and the impact of novel missense variants on the tertiary (three‐dimensional) structure of GDE was evaluated by molecular modeling approach. Eighteen different pathogenic variants were identified, out of which 78% were novel. Novel variants included five nonsense, three small duplications and two small deletions, a splice site variant, and three missense variants. Variations in Exons 4, 14, 19, 24, 27, and 33 accounted for 61% of the total pathogenic variants identified and Allele p.Gly798Alafs*3 showed a high allele frequency of 11%. Molecular modeling study of novel pathogenic missense variants indicated the probable underlying molecular mechanism of adverse impact of variations on the structure and catalytic function of human GDE. Our study is the first large study on GSD III from the Asian subcontinent, which further expands the mutation spectrum of AGL.